Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Inventory (2016 - 2025)

Heron Therapeutics' Inventory history spans 10 years, with the latest figure at $92.7 million for Q4 2025.

  • For Q4 2025, Inventory rose 74.47% year-over-year to $92.7 million; the TTM value through Dec 2025 reached $92.7 million, up 74.47%, while the annual FY2025 figure was $92.7 million, 74.47% up from the prior year.
  • Inventory reached $92.7 million in Q4 2025 per HRTX's latest filing, up from $70.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $92.7 million in Q4 2025 to a low of $100000.0 in Q1 2024.
  • Average Inventory over 5 years is $50.8 million, with a median of $50.2 million recorded in 2021.
  • Peak YoY movement for Inventory: crashed 99.81% in 2024, then soared 56832.0% in 2025.
  • A 5-year view of Inventory shows it stood at $48.4 million in 2021, then increased by 12.8% to $54.6 million in 2022, then decreased by 22.84% to $42.1 million in 2023, then increased by 26.24% to $53.2 million in 2024, then skyrocketed by 74.47% to $92.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Inventory are $92.7 million (Q4 2025), $70.0 million (Q3 2025), and $73.0 million (Q2 2025).